Sort   by:  
 Page size 
UnknownDifferent activity and toxicity of immunotherapy in monozygotic twins diagnosed with early triple-negative breast cancer: a case report.
Not available
S-EPMC11837129 | biostudies-literature
UnknownReal-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer.
Not available
S-EPMC12717040 | biostudies-literature
UnknownAdverse events and impact on quality of life of antibody-drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta-analysis.
Not available
S-EPMC12066883 | biostudies-literature
UnknownSurvival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.
Not available
S-EPMC11846014 | biostudies-literature
UnknownPrognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies.
Not available
S-EPMC10225659 | biostudies-literature
Sort   by:  
 Page size